Furthermore, combining ibrutinib with the BCL‐2 inhibitor venetoclax is a proven and successful treatment option in CLL (Hillmen et al., 2019; Kater et al., 2019), yet resistance can still arise from strong activation of the NF‐κB pathway via microenvironmental agonists such as CD40L and CpG oligodeoxynucleotides (Jayappa et al., 2017). This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.